Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | GLA | P06280 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terazosin SCHEMBL30684952 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL6528 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL5424458 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL41545 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL5427410 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL31284920 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL8057933 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL5525882 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL9053035 | 0.98 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL1133792 | 0.98 | KDM4E (0.96) | KDM4EALDH1A1HPGDGLAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6202 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375376-A1 | STABLE ORAL LIQUID COMPOSITION OF TERAZOSIN | Novitium Pharma LLC (US) | 2025-12-11 | — | — | US | claimed |
| US-12427108-B2 | Stable oral liquid composition of terazosin | Novitium Pharma LLC (US) | 2025-09-30 | — | — | US | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| CN-119528888-A | Preparation method of small-granularity terazosin hydrochloride | 迪嘉药业集团股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2024-08-01 | — | — | US | claimed |
| CN-118169271-A | Method for detecting alpha-adrenergic receptor blocker, SSRI and 5-ARIs and application thereof | 巴中市产品质量检验检测中心 | 2024-06-11 | — | — | CN | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| WO-2024023441-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF POST-TRAUMATIC STRESS SYNDROME | Kinnov Therapeutics (FR) | 2024-02-01 | — | — | WO | claimed |
| EP-4057999-B1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-12-13 | — | — | EP | claimed |
| CN-117092227-A | Method for rapidly screening multiple veterinary drug residues in milk | 黑龙江飞鹤乳业有限公司 | 2023-11-21 | — | — | CN | claimed |
| EP-0724592-B1 | 16-SUBSTITUTED-4-AZA-ANDROSTANE 5-ALPHA-REDUCTASE ISOZYME 1 INHIBITORS | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| WO-1998005308-A2 | TERAZOSIN CAPSULES | NOVARTIS AG (CH) | 1998-02-12 | — | — | WO | claimed |
| WO-1998000159-A1 | USEFUL FORMULATIONS OF ACID ADDITION SALT DRUGS | OXIGENE, INC. (US) | 1998-01-08 | — | — | WO | claimed |
| EP-0728000-A1 | THE USE OF ALFUZOSIN OR TERAZOSIN IN THE TREATMENT OF PREMATURE EJACULATION | SYNTHELABO (FR) | 1996-08-28 | — | — | EP | claimed |
| EP-0536329-B1 | R(+)-TERAZOSIN | ABBOTT LAB (US) | 1996-04-17 | — | — | EP | claimed |
| WO-1995013072-A1 | THE USE OF ALFUZOSIN OR TERAZOSIN IN THE TREATMENT OF PREMATURE EJACULATION | CAVALLINI GIORGIO (IT) | 1995-05-18 | — | — | WO | claimed |
| EP-0536329-A4 | R(+)-TERAZOSIN | — | 1993-05-19 | — | — | EP | claimed |
| EP-0536329-A1 | R(+)-TERAZOSIN. | ABBOTT LAB (US) | 1993-04-14 | — | — | EP | claimed |
| EP-0189336-A1 | Pharmaceutical compositions containing an alpha-blocker and a calcium antagonist | SYNTHELABO (FR) | 1986-07-30 | — | — | EP | claimed |